Regulatory Approval
Eco Animal Health Group Plc
22 April 2016
ECO Animal Health Group plc
(AIM: EAH)
ECO RECEIVES POSITIVE OPINION ON AIVLOSIN® FOR CHICKENS LAYING EGGS FOR HUMAN CONSUMPTION FOR THE EU
ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) for the use of Aivlosin® 625 mg/g water soluble granules in chickens laying eggs for human consumption.
This positive opinion will allow for the medication of drinking water with Aivlosin® for the treatment of respiratory infection caused by Mycoplasma gallisepticum in poultry laying eggs for human consumption with a zero day drug withdrawal period for eggs.
ECO is now able to accelerate the submission of the Aivlosin® regulatory files for the treatment of layers in its key global markets.
Aivlosin®, ECO’s patented antimicrobial, is used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.
Peter Lawrence, Chairman of ECO, commented “This positive opinion from the European regulatory authorities for commercial layers is another encouraging and positive step in the development of Aivlosin® as a fast growing, truly global brand. It underlines ECO’s continued commitment to being a major force in the international market for veterinary pharmaceutical products.â€
Contacts:
ECO Animal Health Group plc Peter Lawrence 020 8336 6190
Marc Loomes 020 8447 8899
Spiro Financial Anthony Spiro 020 8336 6196
Peel Hunt LLP Dan Webster 020 7418 8900
(Nominated Adviser)
ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160421006081/en/